BCAB – bioatla, inc. (US:NASDAQ)

News

BioAtla to Participate in the Citizens JMP Life Sciences Conference
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors [Yahoo! Finance]
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
BioAtla: A Buried ADC Concern Gets Some New Life In 2024 [Seeking Alpha]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com